ABPI Chief Executive Stephen Whitehead issues a statement on the investment in Alzheimer's treatment by the pharmaceutical industry.

 
​​

Stephen Whitehead, Chief Executive of the ABPI, said:

"The industry continues to address unmet medical need in Alzheimer's disease as well as other neurogenerative diseases, which are serious health challenges facing all societies with ageing demographics. Hence there is a pipeline of over 200 candidate medicines in various stages of development for Alzheimer’s disease.

"The pharmaceutical industry continues to innovate new treatments, but the process is often more gradual than is realised, with each new medicine taking possibly 12-15 years to develop, each costing an average £1.15 billion. It is only through these incremental advances in medicine development, as fundamental research uncovers new pathways into these complex diseases, that progress is made. Antibiotics, anti-epileptics, cancer and HIV treatments are all examples of treatments that have vastly improved over the last 10 years, as a result of these developments and continued trials.

"Given the nature of these complex diseases not every trial results in a new treatment and thus withdrawals can occur even in the final stages of development."

 
Print this page icon Print this page
 
Please choose the subject of your enquiry from the list below:
 
Code to enter for submitting the form
Enter the above code here:
Can't read? Try different words.